Schedule a Cognivue DEMO Today 
Follow Us
©2025 Cognivue, Inc. | Privacy Policy | References
Cognivue Launches Real-World Data Collection Project to Study Hearing and Cognitive Function Relationship
12 U.S. Audiology Clinics Participating with the Cognivue ThriveTM Screening Device ROCHESTER, NY, November 16, 2021—Neuroscience company Cognivue, Inc. has launched a nationwide real-world data collection project aimed at confirming a direct…
Cognivue is proud to support Davos Alzheimer’s Collaborative and their global efforts to fight Alzheimer’s Disease
Geneva, 21 September 2021 – The Davos Alzheimer’s Collaborative (DAC) is a global multi-stakeholder partnership that is mobilizing the world against Alzheimer’s disease. DAC announced today it has successfully completed financing of its foundational phase and has launched…
Cognivue, Inc. Initiates Nationwide Clinical Study to Assess Post-COVID-19 Syndrome (Long Haul Syndrome)
ROCHESTER, N.Y., July 8, 2021—Neuroscience company Cognivue, Inc. today announced the initiation of COG-COVID19, an open-label, prospective, two-armed comparison clinical study to assess the impact of COVID-19 on cognitive function. Researchers from…
Cognivue is as Effective as MoCA While Demonstrating Better Test-Retest Reliability for Assessing Cognitive Impairment, According to New Paper
Study Published in Neurological Sciences and Neurosurgery Shows FDA-Cleared Technology as Having Superior Test-Retest Reliability; Affirms Use as Efficient, Easy-to-Use Alternative to Traditional Pencil-and-Paper Assessment Methods ROCHESTER, N.Y., June 25, 2021—Neuroscience company…
Cognivue, Inc. and the American Institute of Balance Announce Inaugural Thought Leader Summit
Cognivue, Inc. and the American Institute of Balance Announce Inaugural Thought Leader Summit June 25-26, 2021 Audiology and otolaryngology leaders will discuss the industry’s role as part of a standard of care…
Cognivue, Inc. Joins Milken Institute’s Alliance to Improve Dementia Care Steering Committee
Cognivue, Inc. Joins Milken Institute’s Alliance to Improve Dementia Care Steering Committee The Alliance seeks to transform and improve the complex health and long-term care systems for individuals at risk for and…
Victor company plays role in world-wide study, seeking to improve Alzheimer’s detection
VICTOR, N.Y. (WROC)- April 27th, 2021: Top Stories
Cognivue to Participate in Major Clinical Study with Global Alzheimer’s Platform
First FDA-cleared computerized test of cognitive function will be evaluated in the Bio-Hermes study; seeks to improve identification and screening…
Cognivue CMO Newsletter, Fall 2020
Dr. Fred Ma addresses the COVID-19 pandemic and the role of cognitive testing. Cognivue CMO Newsletter, Fall 2020
Cognivue Welcomes Karen Parkyn-Michael as Vice President of Marketing and Strategy
Executive Brings More than 25 Years of Strategic and Commercial Experience in Multinational and Emerging Medical Device Companies ROCHESTER, N.Y., December 2, 2021—Neuroscience company Cognivue, Inc. has named Karen Parkyn-Michael as vice…
Cognivue Launches Real-World Data Collection Project to Study Hearing and Cognitive Function Relationship
12 U.S. Audiology Clinics Participating with the Cognivue ThriveTM Screening Device ROCHESTER, NY, November 16, 2021—Neuroscience company Cognivue, Inc. has launched a nationwide real-world data collection project aimed at confirming a direct…
Cognivue is proud to support Davos Alzheimer’s Collaborative and their global efforts to fight Alzheimer’s Disease
Geneva, 21 September 2021 – The Davos Alzheimer’s Collaborative (DAC) is a global multi-stakeholder partnership that is mobilizing the world against Alzheimer’s disease. DAC announced today it has successfully completed financing of its foundational phase and has launched…
Cognivue, Inc. Initiates Nationwide Clinical Study to Assess Post-COVID-19 Syndrome (Long Haul Syndrome)
ROCHESTER, N.Y., July 8, 2021—Neuroscience company Cognivue, Inc. today announced the initiation of COG-COVID19, an open-label, prospective, two-armed comparison clinical study to assess the impact of COVID-19 on cognitive function. Researchers from…
Cognivue is as Effective as MoCA While Demonstrating Better Test-Retest Reliability for Assessing Cognitive Impairment, According to New Paper
Study Published in Neurological Sciences and Neurosurgery Shows FDA-Cleared Technology as Having Superior Test-Retest Reliability; Affirms Use as Efficient, Easy-to-Use Alternative to Traditional Pencil-and-Paper Assessment Methods ROCHESTER, N.Y., June 25, 2021—Neuroscience company…
Cognivue, Inc. and the American Institute of Balance Announce Inaugural Thought Leader Summit
Cognivue, Inc. and the American Institute of Balance Announce Inaugural Thought Leader Summit June 25-26, 2021 Audiology and otolaryngology leaders will discuss the industry’s role as part of a standard of care…
Cognivue, Inc. Joins Milken Institute’s Alliance to Improve Dementia Care Steering Committee
Cognivue, Inc. Joins Milken Institute’s Alliance to Improve Dementia Care Steering Committee The Alliance seeks to transform and improve the complex health and long-term care systems for individuals at risk for and…
Victor company plays role in world-wide study, seeking to improve Alzheimer’s detection
VICTOR, N.Y. (WROC)- April 27th, 2021: Top Stories
Cognivue to Participate in Major Clinical Study with Global Alzheimer’s Platform
First FDA-cleared computerized test of cognitive function will be evaluated in the Bio-Hermes study; seeks to improve identification and screening…
Cognivue CMO Newsletter, Fall 2020
Dr. Fred Ma addresses the COVID-19 pandemic and the role of cognitive testing. Cognivue CMO Newsletter, Fall 2020